‘DOR BioPharma is to collaborate with Dowpharma, to advance the development of DOR’s oral botulism vaccine. The vaccine, BT-VACC, is designed to protect against exposure to botulinum toxin, which is one of five “Category A” bioterrorism threats identified by the US government.

Under the agreement, Dowpharma will use its pfenex expression technology to speed the development process of the vaccine.

Oral administration of BT-VACC produces protective antibodies that afford protection or prolonged survival of treated animals against 30,000 times the lethal dose of botulinum toxin serotype A.’

Read more at DOR BioPharma and Dowpharma to develop bioterrorism vaccine

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Friday, July 29th, 2005 at 2:28 am and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.